RECRUITING

Aromatherapy Inhaler Use for HSCT Distress

Description

The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Conditions

Cancer DistressCancer CopingHematopoetic Stem Cell TransplantAromatherapy
Talk to us

Related Conditions:

Cancer DistressCancer CopingHematopoetic Stem Cell TransplantAromatherapy

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress

Aromatherapy Inhaler Use for HSCT Distress

Condition
Cancer Distress
Intervention / Treatment

-

Contacts and Locations

Stanford

Stanford University, Stanford, California, United States, 94305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Autologous and Allogeneic patients admitted to E1 for planned HSCT
  • * Patients with hematologic malignancies requiring HSCT
  • * No allergies to lavender or peppermint essential oils
  • * Must have received chemotherapy during preparative regimen (single or multi-agent regimen)
  • * Adult patient over 18 years of age
  • * Able to speak, read, and comprehend English
  • * Willing and capable of providing informed consent
  • * Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion
  • * Patients receiving a transplant for a germ cell tumor diagnosis
  • * Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)
  • * Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4
  • * History of scleroderma
  • * History of atrial fibrillation
  • * Known history of G6PD deficiency
  • * Allergic to lavender or peppermint essential oils
  • * Pediatric patient 18 years of age or less
  • * Unable to speak, read, and comprehend English
  • * Unwilling or incapable of providing informed consent

Ages Eligible for Study

19 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Anna Oh, PhD, MPH, RN, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2026-03